Tanzi Maria G, Undre Nasrullah, Keirns James, Fitzsimmons William E, Brown Malcolm, First M Roy
Astellas Pharma Global Development, Northbrook, IL, USA.
Astellas Pharma Europe Ltd, Surrey, UK.
Clin Transplant. 2016 Aug;30(8):901-11. doi: 10.1111/ctr.12763. Epub 2016 Jun 18.
Prolonged-release tacrolimus was developed as a once-daily formulation with ethylcellulose as the excipient, resulting in slower release and reduction in peak concentration (Cmax ) for a given dose compared with immediate-release tacrolimus, which is administered twice daily. This manuscript reviews pharmacokinetic information on prolonged-release tacrolimus in healthy subjects, in transplant recipients converted from immediate-release tacrolimus, and in de novo kidney and liver transplant recipients. As with the immediate-release formulation, prolonged-release tacrolimus shows a strong correlation between trough concentration (Cmin ) and area under the 24-hour time-concentration curve (AUC24 ), indicating that trough whole blood concentrations provide an accurate measure of drug exposure. We present the pharmacokinetic similarities and differences between the two formulations, so that prescribing physicians will have a better understanding of therapeutic drug monitoring in patients receiving prolonged-release tacrolimus.
缓释他克莫司被开发为每日一次的制剂,以乙基纤维素作为辅料,与每日给药两次的速释他克莫司相比,对于给定剂量,其释放更慢且峰浓度(Cmax)降低。本手稿综述了健康受试者、从速释他克莫司转换而来的移植受者以及初发肾和肝移植受者中缓释他克莫司的药代动力学信息。与速释制剂一样,缓释他克莫司在谷浓度(Cmin)与24小时时间-浓度曲线下面积(AUC24)之间显示出强烈相关性,表明谷全血浓度可准确衡量药物暴露情况。我们阐述了两种制剂之间药代动力学的异同,以便开处方的医生能更好地了解接受缓释他克莫司治疗的患者的治疗药物监测。